Back to Search Start Over

Hemicrania Continua: An Update.

Authors :
Al-Khazali HM
Christensen RH
Lambru G
Dodick DW
Ashina H
Source :
Current pain and headache reports [Curr Pain Headache Rep] 2023 Oct; Vol. 27 (10), pp. 543-550. Date of Electronic Publication: 2023 Aug 11.
Publication Year :
2023

Abstract

Purpose of Review: Hemicrania Continua (HC) is a rare and disabling primary headache disorder that is characterized by persistent, unilateral headache with ipsilateral, cranial autonomic symptoms and restlessness or agitation. The diagnosis requires patients to experience an absolute response to therapeutic doses of indomethacin.<br />Recent Findings: HC is diagnosed in in about 1.8% of adult patients who were evaluated for headache in tertiary care services, albeit this estimate should be interpreted with caution. The most prevalent accompanying symptoms appear to be lacrimation, conjunctival injection and restlessness or agitation. However, the available literature is limited by methodologic issues, and the current diagnostic criteria lack clarity on what defines absolute response to indomethacin. More rigorous studies are thus needed to improve our understanding of HC which, in turn, will facilitate better disease management in clinical practice. Here, we provide a comprehensive overview of HC, including its epidemiology, clinical presentation, diagnostic evaluation, and management.<br /> (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1534-3081
Volume :
27
Issue :
10
Database :
MEDLINE
Journal :
Current pain and headache reports
Publication Type :
Academic Journal
Accession number :
37566220
Full Text :
https://doi.org/10.1007/s11916-023-01156-9